AC710 Mesylate NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-27 |
Product Details
| Product Name: AC710 Mesylate | CAS No.: 1351522-05-8 |
| Supply Ability: 10g | Release date: 2025/07/27 |
Product Introduction
Bioactivity
| Name | AC710 Mesylate |
| Description | AC710 Mesylate is a potent PDGFR inhibitor with dissociation constants (Kds) of 0.6 nM for FLT3, 1.57 nM for CSF1R, 1 nM for KIT, 1.3 nM for PDGFRα, and 1.0 nM for PDGFRβ. |
| Animal Research | The antitumor efficacy of AC710 is assessed in a subcutaneous flank-tumor xenograft model in athymic nude mice using the MV4-11cell line. AC710 is dosed at 0.3, 3, and 30 mg/kg for 2 weeks. Tumor growth and body weight are monitored. |
| In vivo | At a dosage of 0.3 mg/kg, AC710 temporarily inhibits tumor growth, which then quickly resumes. However, at dosages of 3 and 30 mg/kg, AC710 induces complete tumor regression, with the reduction in tumor volume remaining for an extended period post-treatment cessation. Furthermore, no loss of body weight is observed in AC710-treated animals across all dosages, suggesting good tolerability in mice. Efficacy of AC710 is also noted in a mouse collagen-induced arthritis (CIA) model, showing significant disease impact in a dose-dependent manner, with noticeable effects starting from a dosage as low as 3 mg/kg over a 15-day period (day 0-14). At higher doses (10 and 30 mg/kg), AC710 is as effective, if not more so, than dexamethasone in reducing joint swelling and inflammation when administered at a safe dose. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | PDGFRβ | PDGFRα | FLT3 | CSF1R | c-Kit | AC-710 Mesylate | AC710 Mesylate | AC 710 Mesylate |
| Inhibitors Related | Nintedanib | Regorafenib monohydrate | Imatinib Mesylate | Sunitinib Malate | Sorafenib | Regorafenib | Ponatinib | Sorafenib tosylate | Lenvatinib mesylate | Imatinib | Pazopanib | Axitinib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP3Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-06-12 | |
| $0.00/25Kg/Bag |
Sinoway Industrial co., ltd.
|
2021-08-05 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY